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CDstructural and mechanical changes differs between them.10
Although histologic alterations in myxomatous valves have
been well described in the past,16-20 only recently have the
mechanical properties of myxomatous mitral valves been ex-
tensively studied,10 and it is shown that myxoid leaflets are
more extensible and less stiff than normal valves. It is also
demonstrated16 that cells of the chordae of myxomatous
valves produce more glycoaminoglycans, giving them their
characteristic thickening and gelatinous nature, which may
account for their mechanical weakness.21 All these patho-
physiologic findings may help to explain why a progressive
incidence of mitral valve incompetence is found after initial
adequate repair. When patients bearing the surgical risks
(ie, use of chordal shortening, nonuse of an annuloplasty
ring, and nonuse of sliding plasty) are excluded from the
analysis, recurrence rate drops from 3.2% per year to 2.4%
per year. This residual rate of 2.4% per year can be attributed
to the phenomenon of valve degeneration. However, two dis-
tinct forms of valve degeneration were described: fibroelastic
deficiency and Barlow disease.11,12 Because Barlow disease
is a more generalized form of valve degeneration, the pro-
gression of the degenerative process in these valves can be
expected to be more pronounced and reflected in the recur-
rence rates of mitral regurgitation. At first glance this is cor-
rect: the recurrence rate in Barlow disease is 6.0% per year
and in fibroelastic deficiency 2.6% per year. However, the
impact of the surgical risk factors is so high that after correc-
tion for these techniques, the residual recurrence rate de-
creases to almost that of fibroelastic deficiency (2.9 vs
2.2% per year).
It can be concluded that the long-term result of mitral
valve repair in Barlow disease is essentially the same as in
fibroelastic deficiency provided optimal surgical techniques
are used. A constant recurrence rate of regurgitation (2%–
3% per year) remains present owing to progression of the
degenerative process in the native valve.
References
1. Flameng W, Herijgers P, Bogaerts K. Recurrence of mitral valve regur-
gitation after mitral valve repair in degenerative valve disease. Circula-
tion. 2003;107:1609-13.
2. Enriquez-Sarano M, Schaff HV, Orszulak TA, Tajik AJ, Bailey KR,
Frye RL. Valve repair improves the outcome of surgery for mitral regur-
gitation: a multivariate analysis. Circulation. 1995;91:1022-8.
3. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA,
Bailey KR, Tajik AJ, et al. Impact of preoperative symptoms on survival
after surgical correction of organic mitral regurgitation: rationale for
optimizing surgical indications. Circulation. 1999;99:400-5.
4. Perier P, Stumpf J, Go¨tz C, Lakew F, Schneider A, Clausnizer B, et al.
Valve repair for mitral regurgitation caused by isolated prolapse of the
posterior leaflet. Ann Thorac Surg. 1997;64:445-50.
5. Gillinov AM, Cosgrove DM, Blackstone EH, Diaz R, Arnold JH,
Lytle BW, et al. Durability of mitral valve repair for degenerative dis-
ease. J Thorac Cardiovasc Surg. 1998;116:734-43.
6. David TE, Omran A, Armstrong S, Sun Z, Ivanov J. Long-term results of
mitral valve repair for myxomatous disease with and without chordal
replacement with expanded polytetrafluoroethylene sutures. J Thorac
Cardiovasc Surg. 1998;115:1279-86.280 The Journal of Thoracic and Cardiovascular Surgery c Feb7. Smedira NG, Selman R, Cosgrove DM, McCarthy PM, Lytle BW,
Taylor PC, et al. Repair of anterior leaflet prolapse: chordal transfer is
superior to chordal shortening. J Thorac Cardiovasc Surg. 1996;112:
287-92.
8. Phillips MR, Daly RC, Schaff HV, Dearani JA, Mullany CJ,
Orszulak TA. Repair of anterior leaflet mitral valve prolapse: chordal re-
placement versus chordal shortening. Ann Thorac Surg. 2000;69:25-9.
9. David TE, Ivanov J, Armstrong S, Christie D, Rakowski H. A compar-
ison of outcomes of mitral valve repair for degenerative disease with
posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg.
2005;130:1242-9.
10. Barber JE, Kasper FK, Ratliff NB, Cosgrove DM, Griffin BP, Vesely I.
Mechanical properties of myxomatous mitral valves. J Thorac Cardio-
vasc Surg. 2001;122:955-62.
11. Carpentier A, Chauvaud S, Fabiani JN, Deloche A, Relland J,
Lessana A, et al. Reconstructive surgery of mitral valve incompetence:
ten-year appraisal. J Thorac Cardiovasc Surg. 1980;79:338-48.
12. Fornes P, Heudes D, Fuzellier JF, Tixier D, Bruneval P, Carpentier A.
Correlation between clinical and histologic patterns of degenerative
mitral valve insufficiency: a histomorphometric study of 130 excised
segments. Cardiovasc Pathol. 1999;8:81-92.
13. Mohty D, Orszulak TA, Schaff HV, Avierinos JF, Tajik JA, Enriquez-
Sarano M. Surgery for valvular heart disease: very long-term survival
and durability of mitral valve repair for mitral valve prolapse. Circula-
tion. 2001;104(suppl I):I1-7.
14. Phillips MR, Daly RC, Schaff HV, Dearani JA, Mullany CJ,
Orszulak TA. Repair of anterior leaflet mitral valve prolapse: chordal re-
placement versus chordal shortening. Ann Thorac Surg. 2000;69:25-9.
15. Adams DH, Anyanwu AC, Rahmanian PB, Abascal V, Salzberg SP,
Filsoufi F. Large annuloplasty rings facilitate mitral valve repair in
Barlow’s disease. Ann Thorac Surg. 2006;82:2096-101.
16. Svensson EC, Huggins GS, Lin H, Clendenin C, Jiang F, Tufs R, et al.
A syndrome of tricuspid atresia in mice with a targeted mutation of the
gene encoding Fog-2. Nat Genet. 2000;25:353-6.
17. Whittaker P, Boughner DR, Perkings DG, Canham PB. Quantitative
structural analysis of collagen in chordae tendineae and its relation to
floppy mitral valves and proteoglycan infiltration. Br Heart J. 1987;
57:264-9.
18. Baker PB, Bansal G, Boudoulas H, Kolibash AJ, Kilman J, Wooley CF.
Floppy mitral valve chordae tendineae: histopathologic alterations.Hum
Pathol. 1988;19:507-12.
19. Wooley CF, Baker PB, Kolibash AJ, Kilman JW, Sparks EA,
Boudoulas H. The floppy, myxomatous mitral valve, mitral valve pro-
lapse, and mitral regurgitation. Prog Cardiovasc Dis. 1991;33:397-433.
20. Tamura K, Fukuda Y, Ishizaki M, Masuda Y, Yamanaka N, Ferrans VJ.
Abnormalities in elastic fibers and other connective-tissue components
of floppy mitral valve. Am Heart J. 1995;129:1149-58.
21. Barber JE, Ratliff NB, Cosgrove DM,Griffin BP, Vesely I. Myxomatous
mitral valve chordae. I: Mechanical properties. J Heart Valve Dis. 2001;
10:320-4.
Discussion
Dr Aubrey C. Galloway (New York, NY). This was an excellent pa-
per. You should be congratulated on achieving echographic and
clinical follow-up over time so that we can draw some significant
conclusions. To review a couple of points: 348 patients, about
24%, had Barlow disease by gross pathologic determination. The
linearized rate of recurrence of mitral regurgitation was higher
clearly in the Barlow population, but you were able to identify cer-
tain other risk factors. Most prominently, you showed, similar to
what others have shown, that chordal shortening does not work
well in Barlow patients and that the absence of an annuloplasty de-
vice or use of a flexible annuloplasty device was associated with
a higher failure rate. In contrast, you showed improved late results
with chordal replacement and rigid devices. Therefore, if you used
those ‘‘optimal techniques,’’ the late recurrence rate dropped to an
acceptable but still significant 2.9% per year over time.ruary 2008
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technique and absence of the use of a rigid ring were predictors of
late recurrence, which you did not put in the presentation but did
put in your manuscript. You also observed that a billowing anterior
leaflet was predictive of late failure in fibroelastic deficiency, which
brings me to my first point. It seems that the gross characterization of
valve disease into Barlow versus fibroelastic deficiency is probably
not that useful or specific a way to fine tune our predictions as to who
is at risk for late failure. There is probably a spectrum of disease that
we have not figured out that is not apparent by gross visual inspec-
tion at the time of surgery. Maybe we need better phenotypic char-
acterizations or even genotypic ways to characterize these valves.
This brings me to the fundamental question: if we use optimal
surgical techniques but still have a built-in failure rate of somewhere
between 2.2% and 2.9%, can a valve phenotype be identified that
would have a high enough risk of failure that chordal replacement
should be done prophylactically since you showed that this tech-
nique improved outcomes?
Dr Flameng. Yes, we clearly do not have any idea what the un-
derlying mechanism of this disease is, and I realize that it might well
be that the spectrum from Barlow to fibroelastic deficiency is one
disease. The point of the paper is that once we recognize the nondu-
rable techniques, we still find that there is a progression of the dis-
ease. There is almost no difference anymore between the global sick
valve and the localized sick valve. If you call it Barlow or fibroelas-
tic deficiency, it does not matter.
Dr Galloway. That was my point. However, the question is,
even in the ‘‘optimal technique’’ group you have almost a 3% per
year failure rate in Barlow type valves. That is 30% over 10 years
in which you are going to have reoperation or 3 or 4+ mitral regur-
gitation.Would you advocate that we intervene prophylactically and
do chordal replacement on those patients now or not, or do you just
accept that late recurrence rate?
Dr Flameng. At the moment, I think we have to accept it, be-
cause there is no technique that can improve it above this or get
rid of this 2% or 3%.
Dr Galloway. That was the conclusion of the panel in the valve
repair postgraduate course. The recommendation was to leave a bil-
lowing but nonprolapsing anterior leaflet alone and repair only the
prolapsing posterior leaflet disease and put in an annuloplasty. It
is just an interesting point for consideration based on your data.
Second, you reported that flexible rings had a higher failure rate.
We have always bought into that idea, agreeing with Dr Carpentier
early on in the concept of more rigid geometric remodeling of the
annulus to make the repaired valve more convex to take tension
off, lower the strain, and therefore lessen the late failure rate. How-
ever, there are a lot of people who do not think that way and there are
a lot of people who believe that flexible devices are appropriate in
patients with degenerative disease. Do you have any data from
your echocardiography as to how valves with flexible devices failed
or why you think your failure rate was higher in that group?
Dr Flameng.We do not have any evidence that a flexible ring is
really inferior to a rigid ring. Not that many patients of our popula-
tion have a flexible ring, and when they do, there are different kinds
of flexible rings. Therefore, it is very difficult to say.
Dr Galloway. One last brief question. You showed in patients
with fibroelastic deficiency that lack of use of sliding plasty was as-
sociated with a higher failure rate. I think most people would use theThe Journal of Thosliding plasty technique mostly in patients who have a big height to
their posterior leaflet, more the Barlow type patients, trying to lower
the height of the posterior leaflet repair after repair. What techniques
did you use in patients with fibroelastic deficiency when you did not
do sliding plasty, and which of these techniques had the highest fail-
ure rate so we can stay away from them?
Dr Flameng. The point is that the sliding leaflet technique as de-
scribed by Professor Carpentier includes reduction of the posterior
leaflet by two additional triangular resections, and then you make
the posterior leaflet short. In fibroelastic deficiency, there is no
need for that. What we do then is just cut the posterior leaflet loose
and diminish the size of the ring by the mattress sutures put from the
left atrium to the ventricle. Then we replace the posterior leaflet. It is
more an annuloplasty than a leaflet plasty.
Dr Galloway. I understand what you did, but what about the
ones that failed? You said that patients who did not get a sliding
plasty had a higher failure rate. What techniques did you use in those
patients?
Dr Flameng. Many of these patients had no ring annuloplasty
because the ring dilatation is not so pronounced in fibroelastic defi-
ciency; you have patients with normal rings or with only mild dila-
tation of the ring. They either received no ring or no sliding
annuloplasty, which induced a higher failure rate.
Dr Galloway. A higher failure rate.
Dr Alain F. Carpentier (Paris, France). Dr Flameng, I enjoyed
your presentation very much. I remember very well when you pub-
lished your paper in Circulation. I was struck by your incidence of
recurrence, which was much higher than the one we had. Now today
you give us at least a part of the answer. Obviously, increasing ex-
perience and careful analysis of the risk factors involved may help to
identify this explanation.
You introduce an interesting distinction between an unfavorable
and a favorable operation. However, there are several factors in-
volved, patient-related or surgeon-related or technique-related, and
it is not easy to identify or to differentiate these different factors.
If we take the patient-related factor first, I notice that you had a rather
small incidence of Barlow compared with fibroelastic deficiency. In
our experience, it is about 50:50. Does it mean that many patients
with Barlow disease in your experience are operated on by valve re-
placement or does it mean that it was difficult for you to identify the
two groups?
Dr Flameng. It is well taken, because the overall rate of repair in
our population of patients having degenerative mitral disease was
nearly 80%, to be exact, 77%. But it changed over the years. In
the late 1980s the rate of repair was much lower than it is now.
Now it is almost 100%. At the beginning, it was mainly the Barlow
valves that were replaced instead of repaired, and that is why the
total number of Barlow valves in the series is lower, as in your
series, for example.
Dr Carpentier. Another question I have relates to the manage-
ment of the P2 prolapse in fibroelastic deficiency. In most instances,
we did not find it necessary to use a sliding plasty, so how do you
explain that? This may also relate to the difficulty in differentiating
the two groups.
Dr Flameng. It is really difficult to differentiate between the
groups, because there is always a gray zone in between. When
you have the clear fibroelastic deficiency as you described it, then
the number would be lower. Some patients we classified as havingracic and Cardiovascular Surgery c Volume 135, Number 2 281
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and consequently we performed more resections and sliding plas-
ties.
Dr Carpentier. I congratulate you for having made the effort to
make the distinction between Barlow and fibroelastic deficiency.
This is important not so much to predict the outcome but to predict
the feasibility and complexity of the repair, which is very important
information for the patient.
Dr Flameng. Thank you for your comment.
Dr David H. Adams (New York, NY). Professor, I would like to
congratulate you for your seminal work in teaching us the difference
between freedom from reoperation and freedom from recurrent
regurgitation, and teaching us to think more about recurrence of
mitral regurgitation. I think you and Tirone David deserve a lot of
credit for looking at your data that way.
I do not think this paper is going to give us the answer that we
all seek, which is the true difference between fibroelastic deficiency282 The Journal of Thoracic and Cardiovascular Surgery c Feand Barlow disease. I would submit to you, and I would like your
response, that there is a gray zone, and you have classified every
patient, which makes your data, in my mind, hard to interpret.
Why not take large ring sizes, for example, where there is less
argument. Take your size 36, 38, and 40 ring groups, and we will
be more comfortable calling that Barlow disease. Take your size
28, 30, and 32 ring groups with single segment prolapse, and we
will be more comfortable calling that fibroelastic deficiency. Do
a comparison of those two groups, and then I think we can get the
answer. What do you think? I think your gray zone is complicating
the interpretation of this information.
Dr Flameng. I do not have a clear answer for that. The only thing
I can say is that we followed Professor Carpentier’s identification of
the disease. And Professor Carpentier is working in Paris. Paris is
the capital of France, which is the biggest country in Europe.
Belgium’s capital is Brussels, and Belgium is the smallest country
in Europe. When it rains in Paris, it drops in Brussels. [Laughter].bruary 2008
